PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
72.86
-0.71 (-0.97%)
Apr 16, 2026, 9:30 AM EDT - Market open
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover PTC Therapeutics stock have a consensus rating of "Buy" and an average price target of $80.65, which forecasts a 10.69% increase in the stock price over the next year. The lowest target is $50 and the highest is $119.
Price Target: $80.65 (+10.69%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 6 | 7 | 7 | 7 | 7 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 1 | 1 | 1 |
| Total | 17 | 17 | 18 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $91 → $76 | Strong Buy → Hold | Downgrades | $91 → $76 | +4.31% | Mar 30, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $90 → $92 | Buy | Maintains | $90 → $92 | +26.27% | Feb 23, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $93 → $86 | Buy | Maintains | $93 → $86 | +18.03% | Feb 20, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $87 → $82 | Hold | Maintains | $87 → $82 | +12.54% | Feb 20, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $97 → $93 | Strong Buy | Maintains | $97 → $93 | +27.64% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
994.77M
from 1.73B
Decreased by -42.52%
Revenue Next Year
1.18B
from 994.77M
Increased by 19.02%
EPS This Year
-0.78
from 7.78
EPS Next Year
1.05
from -0.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.5B | 2.0B | |||
| Avg | 994.8M | 1.2B | |||
| Low | 695.1M | 770.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -14.4% | 103.4% | |||
| Avg | -42.5% | 19.0% | |||
| Low | -59.8% | -22.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.68 | 8.62 | |||
| Avg | -0.78 | 1.05 | |||
| Low | -2.90 | -4.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -65.6% | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.